Breaking News, Collaborations & Alliances

CellProthera Selects CELLforCURE by SEQENS for Phase 3 GMP Manufacturing

CellProthera will tech transfer to CELLforCURE by SEQENS this year, with plans to produce clinical batches starting in 2026. 

By: Rachel Klemovitch

Assistant Editor

CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, has chosen CELLforCURE by SEQENS, as its CDMO partner for its planned Phase 3 trial for ProtheraCytes. CellProthera will tech transfer to CELLforCURE by SEQENS this year, with plans to produce clinical batches in 2026.  ProtheraCytes is an autologous expanded CD34+ stem cell-based therapy aimed at improving heart failure event-free survival following a severe heart attack. Last year, the company presente...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters